Drug Profile
Research programme: G-protein coupled receptor agonists - Confo Therapeutics/Lundbeck
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Confo Therapeutics
- Class Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Psychiatric disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Neurological-disorders in Belgium
- 28 Oct 2021 No recent reports of development identified for research development in Psychiatric-disorders in Belgium
- 13 Nov 2019 Confo Therapeutics has patent protection for ConfoBody in Europen union